DescriptionTrillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.
Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 7.98 +1.75% increase |
| 12.17 -33.28% decrease |
| -3.84 (-32.11%) decrease |
|3-Month|| 7.98 +1.75% increase |
| 13.42 -39.49% decrease |
| -3.44 (-29.76%) decrease |
|52-Week|| 7.98 +1.75% increase |
| 27.12 -70.06% decrease |
| -0.79 (-8.87%) decrease |